JP2012501164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501164A5 JP2012501164A5 JP2011509332A JP2011509332A JP2012501164A5 JP 2012501164 A5 JP2012501164 A5 JP 2012501164A5 JP 2011509332 A JP2011509332 A JP 2011509332A JP 2011509332 A JP2011509332 A JP 2011509332A JP 2012501164 A5 JP2012501164 A5 JP 2012501164A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- gene
- prmt1
- double
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 38
- 101150078958 prmt1 gene Proteins 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 32
- 108091081021 Sense strand Proteins 0.000 claims description 27
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 25
- 230000000692 anti-sense effect Effects 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 230000004071 biological effect Effects 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 claims description 11
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 8
- 206010057644 Testis cancer Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 230000009702 cancer cell proliferation Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 201000003120 testicular cancer Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 108091027568 Single-stranded nucleotide Proteins 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 102000016397 Methyltransferase Human genes 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19041608P | 2008-08-27 | 2008-08-27 | |
| US61/190,416 | 2008-08-27 | ||
| PCT/JP2009/004091 WO2010023877A1 (en) | 2008-08-27 | 2009-08-25 | Prmt1 for target genes of cancer therapy and diagnosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501164A JP2012501164A (ja) | 2012-01-19 |
| JP2012501164A5 true JP2012501164A5 (enExample) | 2012-10-11 |
| JP5764822B2 JP5764822B2 (ja) | 2015-08-19 |
Family
ID=41721060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509332A Expired - Fee Related JP5764822B2 (ja) | 2008-08-27 | 2009-08-25 | がんの治療および診断の標的遺伝子としてのｐｒｍｔ１ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8512944B2 (enExample) |
| EP (1) | EP2329044B1 (enExample) |
| JP (1) | JP5764822B2 (enExample) |
| WO (1) | WO2010023877A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016518336A (ja) | 2013-03-14 | 2016-06-23 | エピザイム，インコーポレイティド | Ｐｒｍｔ１阻害剤としてのピラゾール誘導体およびその使用 |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9365527B2 (en) | 2013-03-14 | 2016-06-14 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| AU2014260433A1 (en) | 2013-03-14 | 2015-09-10 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| HRP20202008T1 (hr) | 2013-03-14 | 2021-02-19 | Epizyme, Inc. | Inhibitori arginin-metiltransferaze i njihove uporabe |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20160271149A1 (en) * | 2015-03-16 | 2016-09-22 | Epinova Therapeutics Corp. | Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation |
| CN109709333B (zh) * | 2018-08-01 | 2021-09-24 | 东南大学 | H4k20、h3k9及h3k36三甲基化量检测试剂在食管癌预后评估中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| CA2262006A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US20020119466A1 (en) * | 2000-08-24 | 2002-08-29 | Rachel Meyers | 46863, a novel human methyltransferase and uses thereof |
| CN1331326A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸 |
| CN1339592A (zh) | 2000-08-21 | 2002-03-13 | 上海博德基因开发有限公司 | 一种新的多肽——蛋白质精氨酸n－甲基转移酶－1(prmt1)11.44和编码这种多肽的多核苷酸 |
| EP1445312B1 (en) | 2001-11-21 | 2012-12-26 | Astellas Pharma Inc. | Method of inhibiting gene expression |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| AU2003211583A1 (en) * | 2002-03-04 | 2003-09-16 | Institute Of Gene And Brain Science | Diagnostics and remedies for malignant brain tumor |
| AU2003282877B9 (en) | 2002-09-25 | 2011-05-12 | University Of Massachusetts | In Vivo gene silencing by chemically modified and stable siRNA |
| WO2004098634A2 (en) | 2003-04-30 | 2004-11-18 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Protein arginine n-methyltransferase 2 (prmt-2) |
| WO2005044976A2 (en) | 2003-06-20 | 2005-05-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| CN105251024A (zh) | 2004-08-23 | 2016-01-20 | 西伦蒂斯私人股份公司 | 眼病的治疗 |
| DE602005023329D1 (de) * | 2004-09-24 | 2010-10-14 | Oncotherapy Science Inc | VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8 |
| CN101189346A (zh) * | 2005-02-28 | 2008-05-28 | 肿瘤疗法科学股份有限公司 | 乳腺癌相关基因znfn3a1 |
| US20090317391A1 (en) * | 2005-04-07 | 2009-12-24 | Novartis Vaccines And Diagnostics Inc. | Cancer Related Genes (PTPE) |
| BRPI0613425A2 (pt) * | 2005-07-21 | 2012-10-30 | Stichting Katholieke Univ | plexina d1, uso de moléculas, moléculas de ligação de plexina d1, composição diagnóstica, composição terapêutica, e, método para identificar moléculas que são capazes de se ligar a plexina dl |
| EP1920056A1 (en) | 2005-07-25 | 2008-05-14 | Oncotherapy Science, Inc. | Compositions and methods for treating breast cancer |
| US7714014B2 (en) * | 2005-12-09 | 2010-05-11 | The Regents Of The University Of California | Targeting GLI proteins in human cancer by small molecules |
| JP5014780B2 (ja) | 2006-12-28 | 2012-08-29 | 株式会社先端生命科学研究所 | メチル化ヘテロジニアス・ヌクレア・リボヌクレオプロテインの免疫学的分析方法及びその利用 |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| EP2221053A1 (de) | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
-
2009
- 2009-08-25 EP EP09809533.4A patent/EP2329044B1/en not_active Not-in-force
- 2009-08-25 WO PCT/JP2009/004091 patent/WO2010023877A1/en not_active Ceased
- 2009-08-25 US US13/060,672 patent/US8512944B2/en not_active Expired - Fee Related
- 2009-08-25 JP JP2011509332A patent/JP5764822B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501164A5 (enExample) | ||
| JP2009502115A5 (enExample) | ||
| Wang et al. | miR-15a-3p and miR-16-1-3p negatively regulate twist1 to repress gastric cancer cell invasion and metastasis | |
| KR102240323B1 (ko) | 유방암 전이의 진단, 예후 및 치료 방법 | |
| JP2012135301A5 (enExample) | ||
| Juneja et al. | Promoter identification and transcriptional regulation of the metastasis gene MACC1 in colorectal cancer | |
| US10705087B2 (en) | Detection method for NTRK3 fusion | |
| EP3272880B1 (en) | Method for the diagnosis, prognosis and treatment of metastatic cancer | |
| US9109259B2 (en) | Detection method for novel ROS1 fusions | |
| JP2008532477A5 (enExample) | ||
| RU2010111135A (ru) | Связанные со злокачественными опухолями гены cdca5. epha7. stk31 и wdhd1 | |
| Bondy-Chorney et al. | RNA binding protein RALY promotes Protein Arginine Methyltransferase 1 alternatively spliced isoform v2 relative expression and metastatic potential in breast cancer cells | |
| KR102547432B1 (ko) | Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| KR20110015013A (ko) | 결장직장암의 평가 방법 및 여기에 사용하기 위한 조성물 | |
| JP7015171B2 (ja) | 新規融合体及びその検出法 | |
| JP2009505633A5 (enExample) | ||
| WO2015012175A1 (ja) | 小細胞肺がんの診断薬及び治療薬 | |
| JP2014523736A5 (enExample) | ||
| WO2014200065A1 (ja) | 大腸癌を治療および／または診断するための組成物ならびにその利用 | |
| RU2011111551A (ru) | C12orf48 как ген-мишень для лечения и диагностики рака | |
| RU2011111387A (ru) | Syngr4 в качестве генов-мишеней для терапии и диагностики рака | |
| JP2005507654A5 (enExample) | ||
| JP2011518541A5 (enExample) | ||
| KR20230007102A (ko) | 유전자내 메틸화 검출을 통한 대장암의 진단 방법 | |
| RU2011111411A (ru) | Oip5 в качестве гена-мишени для терапии и диагностики рака |